Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at "

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at | Ferradini et al. Journal of the International AIDS Society 2011 14 14 http www.jiasociety.Org content 14 1 14 JOURNALOF THE INTERNATIONAL AIDS SOCIETY RESEARCH Open Access High efficacy of lopinavir r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER Calmette Hospital in Phnom Penh Cambodia 1 2 2.3 4 2.3 2 Laurent Ferradini Vara Ouk Olivier Segeral Janin Nouhin Anne Dulioust Chanroeurn Hak IctỉHoIIo Pm Imior5 M lici I omllo3 l lnin4 i in i io2n6 lo n-Pr n nic rìolÌTTỉiccx 3 7 unrl Isabelle Fouiniei Nathalie Leioiie Sopiieak Ngin CHIU vun Mean Jean Fiangois Deniaissy and Eric Nerrienet4 Abstract Background The number of patients on second-line highly active antiretroviral therapy HAART regimens is increasing in resource-limited settings. We describe the outcomes after 24 months for patients on LPV r-based second-line regimens followed up by the ESTHER programme in Phnom Penh Cambodia. Methods Seventy patients who initiated second-line HAART regimens more than 24 months earlier were included and immuno-virological data analyzed. HIV RNA viral load was determined by real-time RT-PCR. HIV-1 drug resistance was interpreted according to the ANRS algorithm. Results Of the 70 patients two were lost to follow up three died and 65 92.8 remained on second-line treatment after 24 months of follow up median duration of treatment 27.4 months . At switch to second-line the median CD4 T cell count was 106 cells mm3 and the median viral load was 4.7 Log10. Second-line regimens prescribed were ddI 3TC LPV r 65.7 ddI TDF LPV r 10.0 ddI AZT LPV r 8.6 and TDF 3TC LPV r 7.1 . The median CD4 T cell gain was 258 cells mm3 at 24 months n 63 . After 24 months of follow up 92.3 60 65 of the patients presented undetectable viral loads giving an overall treatment success rate of 85.7 CI 75.6- 92.0 in intent-to-treat analysis. Conclusions These data suggest that a LPV r-based second-line regimen is associated with a high rate of virological suppression and immune